ClinicalTrials.gg
RecruitingNCT07851454NutReCardUpdated Oct 1, 2026

Walnuts for Cardiorenal Protection in Adults With Chronic Kidney Disease

An interventional study of Daily Walnut Consumption in CKD - Chronic Kidney Disease, Renal Function and Cardiovascular Biomarkers, sponsored by Institut Investigacio Sanitaria Pere Virgili. Recruiting at 1 site in Spain. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.

Planned enrollment
94th of 154
150 · median 252
Started
2026
with 14 others
No phase
28 of 188
9 open now
Primary completion
2028-02
later than 32 of 54 live
Registered
186th of 188
by date

Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 94th largest by planned enrollment of the 154 interventional ones that give a count, is one of 15 that started in 2026, is one of 28 with no phase, reaches primary completion later than 32 of the 54 other live ones, and was the 186th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Renal Insufficiency, Chronic with a site in Spain, or all of them as a file.
02

Study summary

To date, no rigorous randomized controlled trials have demonstrated a protective effect of daily moderate walnut consumption on kidney function or chronic kidney disease (CKD) progression in individuals with CKD.

Objective: To determine the effect of walnut supplementation (30 g/day of raw walnuts) within a Mediterranean diet (MedDiet) based dietary counseling program, compared with the same MedDiet counseling program without walnut supplementation, on kidney function, CKD progression and regression, and classical and emerging cardiovascular risk markers in individuals with CKD. Secondary objectives focus on assessing whether regular walnut consumption as a healthy snack has a positive impact on inflammation, oxidative stress, endothelial dysfunction, and intestinal dysbiosis, conditions intrinsically linked to CKD that play a pathophysiological role in promoting/exacerbating its progression and the development of comorbidities in this vulnerable group of subjects.

Methodology: A 6-month randomized controlled trial will be conducted in 150 men and women aged 45 to 75 years with stable mild to moderate CKD (stage G3a-b), overweight or obesity, and high cardiometabolic risk. The study will compare the effect of two interventions assessed at 3 and 6 months on the following outcomes:

  1. Primary outcomes: a) changes in kidney function assessed by the Estimated Glomerular Filtration Rate based on creatinine and cystatin C (eGFRcr-cys); b) CKD progression; and c) CKD remission
  2. Secondary outcomes: a) urinary albumin-to-creatinine ratio (UACR); b) mineral and bone metabolism parameters, c) anthropometry and body composition (Dual-Energy X-ray Absorptiometry, DXA); d) bone mineral density (DXA); e) diet quality; f) physical activity; g) medication use; h) psychological well-being; i) quality of life; j) classic cardiovascular risk markers; k) iron status and hepatic function; l) inflammation, endothelial function, and oxidation markers; m) gut microbiota
03

Conditions studied

  • CKD - Chronic Kidney Disease
  • Renal Function
  • Cardiovascular Biomarkers

Keywords

  • Nuts
  • Walnut
  • Mediterranean diet
  • Kidney function
  • Chronic kidney disease
  • Inflammation
  • Intestinal dysbiosis
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with stable mild to moderate chronic kidney disease [CKD] (stage G3a-b (estimated [eGFR] 30-\<60mL/min/1.73 m²) and albuminuria stages A1-3 (UACR from \< 30mg/g to ≥ 300 mg/g))
  • 45-75 years old at screening
  • Overweight/obesity ( [BMI] ≥25 and ≤40 kg/m²)
  • Meet at least one of the following conditions:

    (i) Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or use of antihypertensive agents (ii) Triglycerides ≥150 mg/dL, LDL cholesterol ≥160 mg/dL, HDL cholesterol ≤40 mg/dL in men or ≤50 mg/dL in women, or use of lipid-modifying medication (iii) Prediabetes or type 2 diabetes according to the American Diabetes Association (ADA) Standards, or use of glucose-lowering medication.

Exclusion criteria

Exclusion Criteria:

  • Inability to give written
  • CKD caused by polycystic kidney disease, chronic pyelonephritis, and renal dysplasia
  • CKD on renal replacement therapy (hemodialysis, peritoneal dialysis, and kidney transplant recipients)
  • Acute exacerbation of CKD, whether due to extrarenal causes (decompensated heart failure, infectious disease or sepsis, surgical intervention) or due to an outbreak of underlying glomerular or systemic renal pathology, with changes in treatment in the last 2 months.
  • Nut allergy
  • Alcoholism (>50 g/day) or drug abuse
  • Treatment with drugs or cytotoxic agents
  • Any other medical condition that interferes with the completion of the protocol (pregnancy/breastfeeding, history of inflammatory bowel disease, liver failure, cancer or active neoplasms, psychiatric problems)
  • Institutionalization of the participant.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Daily Walnut Consumption

    Participants in the intervention group will consume 30 g/day of raw walnuts in addition to receiving a Mediterranean diet (MedDiet)-based dietary counseling program. To ensure and facilitate adherence, participants will receive two educational leaflets: one providing practical guidance on following a MedDiet and another containing MedDiet-compatible recipes incorporating walnuts. They will also receive written guidance on optimizing phosphorus and potassium intake within a Mediterranean dietary pattern, including information on food sources, hidden additives, and cooking techniques that may reduce mineral content. Walnuts will be provided free of charge and distributed at baseline and at each follow-up visit.

    Other: Daily Walnut Consumption

  • No intervention
    Control: MedDiet-based dietary counseling

    Participants in the control group will receive the same MedDiet-based dietary counseling without walnut supplementation.

Interventions

  • OtherDaily Walnut Consumption

    Participants in the intervention group will consume 30 g/day of raw walnuts for 6 months in addition to receiving a Mediterranean diet (MedDiet)-based dietary counseling program.

06

What researchers measure

Primary outcomes

  1. Change from baseline in renal function

    Renal function will be estimated using the estimated glomerular filtration rate (eGFR) calculated from serum creatinine (eGFRcr), cystatin-C (eGFRcys), or both (eGFRcr-cys), applying the CKD-Epidemiology Collaboration 2021 equation. Serum creatinine and cystatin C concentrations will be obtained from routine biochemical analyses performed as part of the participants' standard clinical care at the hospital.

    Time frame: Participants will be followed for 6 months, with renal function assessments conducted at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.

  2. Chronic Kidney Disease (CKD) Progression

    CKD progression will be assessed using eGFRcr-cys and defined as the first occurrence, during the 6-month intervention period, of any of the following criteria: (i) a decline in eGFRcr-cys of \>2.5 mL/min/1.73 m² from baseline; (ii) a relative decline in eGFRcr-cys of \>10% from baseline; or (iii) progression to a more advanced stage of kidney function impairment, defined as a transition from G3a to G3b or from G3b to G4 or higher.

    Time frame: CKD progression will be evaluated at the end of the 6-month follow-up period.

  3. Chronic Kidney Disease (CKD) remission

    CKD remission will be assessed using eGFRcr-cys and defined as the first occurrence, during the 6-month intervention period, of any of the following criteria: (i) an increase in eGFRcr-cys of \>2.5 mL/min/1.73 m² from baseline; or (ii) improvement to a less advanced stage of kidney function impairment, defined as a transition from G3b to G3a or from G3a to G2 or lower.

    Time frame: CKD remission will be evaluated at the end of the 6-month follow-up period.

Secondary outcomes

  1. Change from baseline in urinary albumin-to-creatinine ratio (UACR)

    The urinary albumin-to-creatinine ratio (UACR, mg/g) will be calculated from urinary albumin and creatinine concentrations measured in first-morning urine samples collected during routine clinical follow-up at the hospital by qualified healthcare personnel, following standard collection and laboratory procedures.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period

  2. Change from baseline in mineral and bone metabolism markers

    Mineral and bone metabolism markers, including potassium, phosphorus, calcium, vitamin D, and parathyroid hormone, will be measured using standardized methods as part of routine fasting blood biochemical analyses.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  3. Change from baseline in body weight

    Body weight will be measured in kilograms (kg) by trained personnel using a calibrated scale, with participants lightly dressed and barefoot.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  4. Change from baseline in waist circumference

    Waist circumference will be measured in centimeters (cm) by trained personnel at the midpoint between the lowest rib and the iliac crest, using a non-stretchable anthropometric tape.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  5. Change from baseline in Body Mass Index (BMI)

    Body weight and height will be used to calculate body mass index (BMI), expressed in kg/m².

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  6. Change from baseline in body composition

    Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measures of general adiposity, such as total fat mass in grams and total body fat percentage, and regional adiposity, including trunk, leg, android, and gynoid fat mass in grams.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  7. Change from baseline in bone mineral density

    Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DXA).

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  8. Change from baseline in diet quality

    Diet will be assessed using a validated 143-item semiquantitative food frequency questionnaire and the 14-item Mediterranean Diet Adherence Screener (MEDAS). The Mediterranean Diet Adherence Screener score ranges from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  9. Change from baseline in physical activity

    Physical activity will be assessed using the validated Registre Gironí del Cor (REGICOR) questionnaire, which estimates energy expenditure in total leisure-time physical activity and according to intensity, including light, moderate, and vigorous activity. Physical activity will be expressed in metabolic equivalents (METs), with higher values indicating greater levels of physical activity.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  10. Change from baseline in medication use affecting glomerular hemodynamics

    Medication use will be assessed by administering a general questionnaire by trained personnel, and from the patient's medical history.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.

  11. Change from baseline in severity of depressive symptoms

    Severity of depressive symptoms will be evaluated using the self-administered Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a validated and widely used tool, composed of nine items scored from 0 to 3 (max. 27), which correspond to the DSM-IV criteria and allow depression to be classified as minimal, mild, moderate, moderately severe and severe. Higher scores indicate greater severity of depressive symptoms.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  12. Change from baseline in severity of anxiety symptoms

    Severity of anxiety symptoms will be evaluated using the self-administered Generalized Anxiety Disorder-7 (GAD-7) questionnaire, a brief seven-item scale in which each item is scored from 0 to 3, with a total score from 0 to 21. Higher scores indicate greater severity of anxiety symptoms.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  13. Change from baseline in quality of life

    Quality of life will be assessed using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire, a validated instrument for individuals with mild-to-moderate chronic kidney disease that includes the 12-Item Short Form Health Survey (SF-12) and kidney disease-specific subscales: Symptoms and Problems, Effects of Kidney Disease, and Burden of Kidney Disease. Scores for each domain range from 0 to 100, with higher scores indicating better health-related quality of life and a lower perceived burden of disease.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  14. Change from baseline in fasting glucose

    Fasting blood glucose will be measured in mg/dL using standardized methods as part of routine fasting blood biochemical analyses.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.

  15. Change from baseline in glycated hemoglobin

    Glycated Hemoglobin (%) will be measured using standardized methods as part of routine fasting blood biochemical analyses.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  16. Changes from baseline in lipid profile

    Total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-C, triglycerides and lipoprotein A will be measured in mg/dL, using standardized methods as part of routine fasting blood biochemical analyses.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  17. Change from baseline in blood pressure

    Systolic and diastolic blood pressure (mmHg) will be determined after 5 minutes of rest by trained personnel, in triplicate using a semi-automatic oscillometric blood pressure monitor. The participant will be seated and will use their non-dominant arm.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.

  18. Change from baseline in iron status markers

    Iron status markers (serum iron, ferritin, transferrin, and transferrin saturation), will be measured using standardized methods as part of routine fasting blood biochemical analyses.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.

  19. Change from baseline in hepatic function markers

    Hepatic function markers (AST, ALT, and GGT) will be measured using standardized methods as part of routine fasting blood biochemical analyses.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.

  20. Change from baseline in lipoprotein profile (particle composition and size)

    Lipoprotein profile, including VLDL, LDL, and HDL subfractions composition and size, will be analyzed in fasting blood samples stored at -80 °C in the Biobank using the Advanced Lipoprotein Profile Liposcale® test, based on proton nuclear magnetic resonance (H-NMR) spectroscopy.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  21. Change from baseline in oxidative markers

    Oxidative stress markers, including oxidized low-density lipoprotein (LDL-ox) and malondialdehyde (MDA), will be measured in fasting blood samples stored at -80 °C in the Biobank using commercially available enzyme-linked immunosorbent assays (ELISAs).

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  22. Change from baseline in inflammatory markers

    Inflammatory markers, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), adiponectin, and leptin, will be measured in fasting blood samples stored at -80 °C in the Biobank using a multiplex immunoassay.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  23. Change from baseline in endothelial function markers

    Endothelial function markers (VCAM-1, ICAM-1, E-selectin, and P-selectin) will be assessed in fasting blood samples stored at -80 °C in the Biobank using a multiplex immunoassay.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

  24. Change from baseline in gut microbiota composition

    Gut microbiota composition will be assessed by shotgun metagenomic sequencing following DNA extraction, with subsequent taxonomic characterization of microbial diversity and functional potential using established bioinformatics pipelines. Participants will receive instructions and a collection kit for stool sample collection. Samples will be submitted frozen, processed, aliquoted, and stored at -80 °C in the Biobank until analysis.

    Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 18 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Oct 1, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Jun 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851454
Lead sponsor
Institut Investigacio Sanitaria Pere Virgili
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Aug 4, 2026
Primary completion
Feb 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Andrés Díaz López, PhD
Contact
andres.diaz@urv.cat
+34 977759372
Verónica Ruíz García, PhD
Contact
vruiz.hj23.ics@gencat.cat
+34 677150430

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion